Paysign Q1 revenue $13.2M (+30% YoY); net income $309k vs loss; reaffirms FY guidance

Paysign, Inc.

2024-Q1 EPS reported $0.01 revenue$13,190,074

Total revenue $13.2M, up 30% YoY; net income $309k ($0.01 diluted EPS) vs net loss $160k in Q1 2023.
Adjusted EBITDA $1.7M, up 135% from $720k; diluted adj. EBITDA per share $0.03 vs $0.01.
Pharma patient affordability revenue surged 305% YoY; added 10 net new programs, ending quarter with 53 active.
Plasma revenue up 11% YoY; 469 plasma centers (net +5); avg revenue per center per month $7,414 (+5%).
Confirms FY 2024 guidance: revenue $54.5M–$56.7M, adjusted EBITDA $8.0M–$9.0M; Q2 revenue expected +27.5% YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Paysign, Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $13.2 million, net income $309 thousand, EPS $0.01.

Period: the fiscal quarter ended March 31, 2024
Revenue: $13.2 million
Net income: $309 thousand
EPS: $0.01
Result: reported results

Exact text from the filing

First quarter 2024 total revenues of $13.2 million

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Paysign, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-003052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.